The multiple roles of KDM6B in various organs or systems make it a potential therapeutic target for some diseases; for example, KDM6B is upregulated in blood disorders, and inhibition of its negative regulator AP-1 in Kdm6b-deficient hematopoietic stem cells restores the functional defects (Mallaney et al. 2019). This evidence concerns the gene KDM6B and hematologic disorder.